What each GLP-1 is approved for
A denial often turns on whether the drug is prescribed for a use on its FDA label. Approved uses include (check the current label, which can add uses):
- Ozempic (semaglutide): improving blood sugar control in adults with type 2 diabetes; reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reducing the risk of kidney decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (label on DailyMed).
- Wegovy (semaglutide): reducing excess body weight and keeping it off in adults and children 12 and older with obesity, or adults with overweight and a weight-related condition, and reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight (label on DailyMed).
- Mounjaro (tirzepatide): improving blood sugar control in adults and children 10 and older with type 2 diabetes (label on DailyMed).
- Zepbound (tirzepatide): reducing excess body weight and keeping it off in adults with obesity, or with overweight and a weight-related condition, and treating moderate to severe obstructive sleep apnea in adults with obesity (label on DailyMed).
Whether your plan covers a drug for weight management at all is set by your plan’s drug list, not by the label. Read the plan’s coverage policy for the drug before you appeal.
Got a denial letter? Upload a PDF or a photo of it, check the details we read from it, and we’ll draft your appeal.
Start my appealFree, always. No account. You review every word before you send it — and we never send anything to your insurer. You do.
How step therapy works
Step therapy (also called “fail first”) means the plan covers the prescribed drug only after you have tried one or more drugs it prefers, such as metformin for type 2 diabetes. The plan’s coverage policy lists the steps and how long each trial must last. Ask your plan for that policy in writing: your appeal answers it point by point.
Grounds for a step-therapy exception
Your doctor asks the plan for an exception (sometimes called an override or formulary exception) and explains which of these applies:
- Already tried: you took the required drug before, under this plan or an earlier one, and it did not work or caused side effects. Pharmacy records and chart notes with dates and doses are the evidence.
- Unsafe for you: the required drug is contraindicated, for example because of your kidney function or another condition, or is expected to cause harm given your history.
- Not right for your condition: the required drug is not expected to work for you, or the prescribed drug is on label for a condition you have and the step drug is not.
- Already stable: you are doing well on the prescribed drug and switching would put that at risk.
Many states have step-therapy laws that list exception grounds and set response deadlines for state-regulated plans. AppealArmor quotes your state’s provision when your state is on our list and your plan is an individual plan or a fully insured employer plan.
How fast your plan must decide
- Medicare Part D: an exception request must be decided within 72 hours, or 24 hours if expedited, after the plan receives your prescriber’s supporting statement (42 CFR 423.568 and 423.572).
- Employer plans: an urgent care claim must be decided within 72 hours (29 CFR 2560.503-1(f)(2)(i)); other deadlines are in the same rule. Your plan documents and denial letter state the deadlines that apply to you.
- Individual and state-regulated plans: the federal claims rules apply (45 CFR 147.136), and your state’s step-therapy law may set a shorter deadline.
How to appeal a GLP-1 denial
- Read the denial. Note the exact reason and the coverage policy it cites, and the deadline to appeal.
- Ask your doctor for a letter. It should name the drug, your diagnosis, the drugs already tried with dates and results, and which exception ground applies.
- Ask for a fast decision if waiting could seriously harm your health. Your doctor can say so in the request.
- File the internal appeal. Answer the stated reason, attach the records, and keep a copy.
- Ask for an independent external review if the plan says no again. See HealthCare.gov on external review; Medicare Part D has its own independent review level.
Illustrative examples: how these appeals are built
These are illustrative composite examples, not real patients or real outcomes. Names and details are made up to show how this kind of appeal is usually built.
Wegovy refused as “cosmetic”
Situation: an adult with obesity and high blood pressure is refused Wegovy as a cosmetic use.
Appeal: the doctor’s letter shows the prescription matches the FDA label (obesity with a weight-related condition) and quotes the plan’s own coverage criteria.
Ozempic step therapy with a prior metformin trial
Situation: the plan requires a metformin trial first, but the patient took metformin two years earlier under another plan and stopped because of side effects.
Appeal: pharmacy records and chart notes document the earlier trial, and the request asks for an exception on the “already tried” ground.
Mounjaro when metformin is unsafe
Situation: the plan requires metformin first, but the patient’s kidney function makes it unsafe.
Appeal: the doctor’s letter cites the lab results and the contraindication, and asks for an exception on the “unsafe for you” ground.
Frequently Asked Questions
What is step therapy?
A plan rule that covers the prescribed drug only after you have tried one or more drugs the plan prefers. The plan’s coverage policy lists the steps.
Can my doctor ask to skip step therapy?
Yes. Your doctor can ask for an exception and explain why the required drug was already tried, would be unsafe for you, or is not right for your condition.
How fast must a Medicare Part D plan decide a GLP-1 exception?
Within 72 hours, or 24 hours if expedited, after the plan receives your prescriber’s supporting statement (42 CFR 423.568 and 423.572).
Is Ozempic approved for weight loss?
No. Ozempic’s FDA label covers adults with type 2 diabetes, including cardiovascular and kidney risk reduction for some of them. Wegovy, which also contains semaglutide, is the version approved for weight management.
What if my plan says no again?
Ask for an independent external review. The reviewer’s decision is binding on the insurer (45 CFR 147.136(d)); Medicare Part D has its own independent review level.